The anti-epileptic drug lacosamide (Vimpat®) has anxiolytic property in rodents

European Journal of Pharmacology

Volumn 624, Issue 1-3, 2009, Pages 1-9

  Higgins, Guy A ^a   Breysse, Nathalie ^a   Undzys, Elijus ^a   Kuo, Calvin ^a   Joharchi, Narges ^a   Derksen, D Richard ^a   Xin, Tao ^a   Isaac, Methvin ^a   Slassi, Malik ^a  

^a NPS Pharmaceuticals   (Canada)

Author keywords

(Mouse); (Rat); Anxiety; Conditioned fear; Diazepam; Hypothermia; Lacosamide; Pregabalin; Sodium valproate

Indexed keywords

DIAZEPAM; HARKOSERIDE; PREGABALIN; SODIUM CHANNEL; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DECISION MAKING; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; EMOTIONALITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; SEIZURE; TRANQUILIZING ACTIVITY; WORKING MEMORY;

ACETAMIDES; ANIMALS; ANTI-ANXIETY AGENTS; ANTICONVULSANTS; ANXIETY; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROSHOCK; MALE; MEMORY; MICE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; SEIZURES; SODIUM CHANNELS;

EID: 70350723590     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.09.050     Document Type: Article

References (40)

1. Aliyev N.A., and Aliyev Z.N. Valproate (depikine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: randomized, double-blind placebo controlled study. Eur. Psychiatry 23 (2008) 109-114
2. Ben-Menachem E., Biton V., Jatuzis D., Abou-Khalil B., Doty P., and Rudd G.D. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 40 (2007) 1308-1317
3. Beyreuther B.K., Freitag J., Heers C., Krebsfanger N., Scharfenecker U., and Stohr T. Lacosamide: a review of preclinical properties. CNS Drug Rev. 13 (2007) 21-42
4. Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Perucca E., and Tomson T. Progress report on new epileptic drugs: a summary of the 8th Eilat Conference (EILAT VIII). Epilepsy Res. 73 (2007) 1-52
5. Blackburn-Munro G., and Blackburn-Munro R.E. Chronic pain, chronic stress and depression: coincidence or consequence?. J. Neuroendocrinol. 13 (2001) 1009-1023
6. Bouwknecht A.J., Olivier B., and Paylor R.E. The stress-induced hyperthermia paradigm as a physiological animal model for anxiety: a review of pharmacological and genetic studies in the mouse. Neurosci. Biobehav. Rev. 31 (2007) 41-59
7. Broekkamp C.L., Rijk H.W., Joly-Gelouin D., and Lloyd K.L. Major tranquilizers can be distinguished from minor tranquilizers on the basis of effects on marble burying and swim-induced grooming in mice. Eur. J. Pharmacol. 126 (1986) 223-229
8. Choi D., Stables J.P., and Kohn H. Synthesis and anti-convulsant activities of N-benzyl 2-acetamidopropionamide derivatives. J. Med. Chem. 39 (1996) 1907-1916
9. Corbett R., Fielding S., Cornfeldt M., and Dunn R.W. GABAmimetic agents display anxiolytic-like effects in the social interaction and elevated plus maze procedures. Psychopharmacology 104 (1991) 312-316
10. Davis L.L., Ryan W., Adinoff B., and Petty F. Comprehensive review of the psychiatric uses of valproate. J. Clin. Psychopharmacol. 20 (2000) 1S-17S
11. Dunnett S.B. Comparative effects of cholinergic drugs and lesions of the nucleus basalis or fimbria-fornix on delayed matching in rats. Psychopharmacology 87 (1985) 357-363
12. Errington A.C., Stohr T., Heers C., and Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of Voltage-gated sodium channels. Mol. Pharmacol. 73 (2008) 157-169
13. Field M.J., Oles R.J., and Singh L. Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity. Br. J. Pharmacol. 132 (2001) 1-4
14. Field M.J., Cox P.J., Stott E., Melrose H.L., Offord J., Su T.Z., Bramwell S., Corradini L., England S., Wilks J., Kinloch R., Hendrich J., Dolphin A.C., Webb T., and Williams D. Identification of the alpha2-delta-1 subunit of voltage dependent calcium channels as a novel molecular target for pain mediating the analgesic actions of pregabalin. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 17537-17542
15. Gardner C.R., and Piper D.C. Effects of agents which enhance GABA-mediated neurotransmission on licking conflict in rats and exploration in mice. Eur. J. Pharmacol. 83 (1982) 25-33
16. Halasz P., Kalviainen R., Mazurkiewicz-Beldzinska M., Rosenow F., Doty P., Hebert D., and Sullivan T. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 50 (2009) 443-453
17. Hao J.-X., Stohr T., Selve N., Wiesenfeld-Hallin Z., and Xu X.-J. Lacosamide, a new anti-epileptic, alleviates neuropathic pain-like behaviours in rat models of spinal cord or trigeminal nerve injury. Eur. J. Pharmacol. 553 (2006) 135-140
18. Higgins, G.A., Breysse, N., Undzys, E., Derksen, R., Jeffrey, M., Scott, B.W., Xin, T., Rouchard, C., Bressand, K., DePaulis, A., Burnham, W.M., in press. Comparative study of five anti-epileptic drugs on a translational cognitive measure in the rat: relationship to antiepileptic property. Psychopharmacology. doi:10.1007/S00213-009-1682-5.
19. Kirkby D.L., and Higgins G.A. Characterization of perforant path lesions in rodent models of memory and attention. Eur. J. Neurosci. 10 (1998) 823-838
20. Lees G., Stohr T., and Errington A.C. Stereoselective effects of the novel anti-convulsant lacosamide against 4-AP induced epileptiform activity in rat visual cortex in vitro. Neuropharmacology 50 (2006) 98-110
21. Martin J.R., Ballard T.M., and Higgins G.A. Influence of the 5-HT2C receptor antagonist, SB-242084, in tests of anxiety. Pharmacol. Biochem. Behav. 71 (2002) 615-625
22. Mathiasen L.S., Rodgers R.J., and Mirza N.R. Comparative effects of nonselective and subtype-selective gamma-aminobutyric acidA receptor positive modulators in the rat conditioned emotional response test. Behav. Pharmacol. 18 (2007) 191-203
23. Meldrum B.S., and Rogawski M.A. Molecular targets for antiepileptic drug development. Neurotherapeutics 4 (2007) 18-61
24. Mirza N.R., Bright J.L., Stanhope K.J., and Wyatt A. Lamotrigine has an anxiolytic-like profile in the rat conditioned emotional response test of anxiety: a potential role for sodium channels?. Psychopharmacology 180 (2005) 159-168
25. Munro G., Erichsen H.K., and Mirza N.R. Pharmacological comparison of anticonvulsant drugs in animal models of persistant pain and anxiety. Neuropharmacology 53 (2007) 609-618
26. Nicolas L.B., Kolb Y., and Prinssen E.P.M. A combined marble burying-locomotor activity test in mice: a practical screening test with sensitivity to different classes of anxiolytics and antidepressants. Eur. J. Pharmacol. 547 (2006) 108-115
27. Perucca E., Yasothan U., Clincke G., and Kirkpatrick P. Lacosamide. Nature Rev. Drug Discovery 7 (2008) 973-974
28. Rauck R.L., Shaibani A., Biton V., Simpson J., and Koch B. Lacosamide in painful diabetic neuropathy. A Phase 2 double-blind placebo-controlled study. Clin. J. Pain 23 (2007) 150-156
29. Rickels K., Pollack M.H., Feltner D.E., Lydiard B., Zimbroff G.L., and Pande A.C. Pregabalin for treatment of generalized anxiety disorder. A 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch. Gen. Psychiatry 62 (2005) 1022-1030
30. Rogawski M.A., and Loscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat. Med. 10 (2004) 685-692
31. Rundfeldt C., and Loscher W. Anticonvulsant efficacy and adverse effects of phenytoin during chronic treatment in amygdala-kindled rats. J. Pharm. Exp. Ther. 266 (1993) 216-223
32. Sanger D.J. Effects of buspirone and related compounds on suppressed operant responding in rats. J. Pharm. Exp. Ther. 254 (1990) 420-426
33. Shaibani A., Biton V., Rauck R., Koch B., and Simpson J. Long-term oral lacosamide in painful diabetic neuropathy: a two-year open-label extension trial. Eur. J. Pain 13 (2009) 458-463
34. Sheets P.L., Heers C., Stoehr T., and Cummins T.R. Differential block of sensory neuronal voltage-gated sodium channels by lacosamide [(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide], lidocaine, and carbamazepine. J. Pharm. Exp. Ther. 326 (2008) 89-99
35. Stanhope K.J., and Dourish C.T. Effects of 5-HT1A receptor agonists, partial agonists and a silent antagonist on the performance of a conditioned emotional response test in the rat. Psychopharmacology 128 (1996) 293-303
36. Stanhope K.J., McLenachan A.P., and Dourish C.T. Dissociation between cognitive and motor/motivational deficits in the delayed matching to position test: effects of scopolamine, 8-OH DPAT and EAA antagonists. Psychopharmacology 122 (1995) 268-280
37. Stohr T., Kupferberg H.J., Stables J.P., Choi D., Harris R.H., Kohn H., Walton N., and White H.S. Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res. 74 (2007) 147-154
38. Taylor C.P., Angelotti T., and Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel α2-δ (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 73 (2007) 137-150
39. Vellucchi S.V., and Webster R.A. The role of GABA in the anticonflict action of sodium valproate and chlordiazepoxide. Pharmacol. Biochem. Behav. 21 (1984) 845-851
40. Vlaeyen J.W., and Linton S.J. Fear-avoidance and its consequences in chronic musculoskeletal pain: a state of the art. Pain 85 (2000) 317-332